#ENLV hashtag - Bluesky

Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 Enlivex (Nasdaq: ENLV) reported 2025 audited results with net income $1.23 billion and diluted EPS $25.48, driven by unrealized appreciation in its treasury and treasury-related derivative assets. The company reported $2.31 billion in treasury assets, $1.93 billion shareholders' equity and $30.0 million in cash and short-term digital investments. Enlivex reiterates a dual strategy combining clinical-stage longevity therapeutics and a prediction-markets-backed treasury model and will host a webcast on March 25, 2026 at 09:00 am ET to discuss results.

1 week ago

#ENLV Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48

www.stocktitan.net/news/ENLV/enlivex-report...

0 0 0 0

Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program $21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor The Company exercised an option to acquire additional 3,030,303,030 RAIN tokens at $0.0033 per token, a 62%

1 week ago

#ENLV Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program

www.stocktitan.net/news/ENLV/enlivex-announ...

0 0 0 0

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange Enlivex (Nasdaq: ENLV) announced that its treasury token RAIN began trading on the KuCoin exchange effective January 6, 2026. The listing places RAIN on a major global venue that serves more than 40 million users and ranks among the top ten cryptocurrency exchanges.Company commentary says the KuCoin listing is expected to expand global market access and secondary liquidity for Enlivex's primary digital treasury holding. KuCoin offers spot trading, derivatives, and yield services and has a strong user base in Southeast Asia. RAIN is described as the governance and utility token of a decentralized predictions and options protocol on Arbitrum.

2 months ago

#ENLV Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange

www.stocktitan.net/news/ENLV/enlivex-treasu...

0 0 0 0

Trade Alerts, Monday November 24, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks gapping up in trading, Mon Nov 24th - #YDES #HSAI #VOR #SLRX #NXTC #MXL #ENLV #CLLS #BLFY #AEHL #MAGN #GNK #CMDB #BFLY - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Stock Master

@stockmaster70.bsky.social

4 months ago

📢 Stocks Trending NOW: #NVO #OSCR #GOOG #NOVO-B.CO #BABA #DVLT #ENLV #UNH #LLY #GOOGL

0 0 0 0

MarketTwits

@markettwits.bsky.social

4 months ago

Enlivex Therapeutics plans to raise $212 million to purchase #RAIN tokens for its balance sheet

#ENLV = +50%

0 0 0 0

Leading Indicators, Wednesday November 12, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks with declining money flow, Wed Nov 12th - #SAVA #ORGN #MAMA #LASR #KOPN #ICHR #HCAT #GNPX #ENLV #DOGZ #CBAT #WW #WEST #UROY #TREE #PDFS #BRCB #SHO #RMT #PACS #NRGV #IIPR #HPP #FF #EE - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

72% Pain Reduction: Enlivex's Allocetra Demonstrates Breakthrough Results in Knee Osteoarthritis Trial Allocetra therapy shows 72% pain reduction and 95% function improvement in age-related osteoarthritis patients vs placebo in Phase I/II trial. No severe adverse events reported.

7 months ago

#ENLV Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis

www.stocktitan.net/news/ENLV/enlivex-announ...

0 0 0 0

Leading Indicators, Tuesday July 29, 2025 – Crystal Equity Research

8 months ago

Small-cap stocks in new uptrend with AROON Oscillator, Tue Jul 29th - #SNDX #QIPS #PDLB #OFIX #MASS #GALT #ENLV #COMM #BTMD #AIP #XPRO #SRI #QD #PDM #MMI #NABL #LFT #INSW #FLNG #CSTM - More: crystalequityresearch.com/leading-indi... - #smallcap

1 0 0 0

Enlivex Phase II Trial Data for 134 Knee Osteoarthritis Patients Set for August 18 Reveal 134-patient Phase II trial completed 3-month follow-up for Allocetra in knee osteoarthritis. Key efficacy and safety data analysis underway. See full results August 18.

8 months ago

#ENLV Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data

www.stocktitan.net/news/ENLV/enlivex-reaffi...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks with strong volume gains, Mon Jun 16th - #SAGE #RDWR #PPIH #OSS #NEON #MULN #IKPT #FARO #ENLV #DWSN #CODA #BEAT #AERT #TE #SST #PERF #HPP #EQV #BPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 1 0

Major Milestone: 133-Patient Phase II Trial Completed for Revolutionary Knee Osteoarthritis Treatment Allocetra Novel Allocetra therapy advances with completed Phase II enrollment of 133 patients. Promising Phase I data sets stage for August 2025 results. Get insights.

11 months ago

#ENLV Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

www.stocktitan.net/news/ENLV/enlivex-announ...

0 0 0 0

Groundbreaking TMJ Treatment Trial Begins: Enlivex Targets Major Medical Need Novel Allocetra therapy enters clinical testing at top-ranked Sheba Medical Center, targeting TMJ osteoarthritis affecting millions globally. See trial details inside.

1 year ago

#ENLV Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

www.stocktitan.net/news/ENLV/enlivex-announ...

0 0 0 0

Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win Enlivex's Allocetra gains Chinese patent protection through 2040, while showing 47% pain reduction in osteoarthritis trial with 83% patient response rate after 6 months.

1 year ago

#ENLV Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

www.stocktitan.net/news/ENLV/enlivex-receiv...

0 0 0 0

Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported Enlivex reports 47% pain reduction and 83% response durability at 6 months in Phase I/II Allocetra trial for knee osteoarthritis, signaling potential breakthrough treatment.

1 year ago

#ENLV Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

www.stocktitan.net/news/ENLV/enlivex-therap...

0 0 0 0

Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted Enlivex refutes fraudulent claims of suspended trading, confirms shares actively trading on NASDAQ/TASE. Company pursuing legal action against false report publishers.

1 year ago

#ENLV Enlivex Issues Urgent Statement on Fraudulent News Dissemination

www.stocktitan.net/news/ENLV/enlivex-issues...

0 0 0 0

Enlivex Therapeutics Advances Allocetra Program with New Phase I Trial for TMJ Osteoarthritis Treatment Enlivex receives approval to evaluate Allocetra in TMJ osteoarthritis patients at world-renowned Sheba Medical Center. Trial targets treatment-resistant cases.

1 year ago

#ENLV Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

#clinicaltrial #news #StockMarket

www.stocktitan.net/news/ENLV/enlivex-receiv...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

BREAKING NEWS: ( NASDAQ: #ENLV ) Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

#StockMarket #News

0 0 0 0

Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study | ENLV Stock News Phase I/II trial reveals significant improvements with Allocetra™ treatment: 50% less knee pain, 42% better function, and 83% patient response rate. Phase II enrollment now underway.

1 year ago

#ENLV Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

#StockMarket #stocks #investing

www.stocktitan.net/news/ENLV/enlivex-announ...

0 0 0 0

1 year ago

#ENLV Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

www.stocktitan.net/news/ENLV/join-enlivex-t...

0 0 0 0

1 year ago

#ENLV Enlivex Adopts Bitcoin Treasury Reserve Strategy

www.stocktitan.net/news/ENLV/enlivex-adopts...

0 0 0 0